353 related articles for article (PubMed ID: 22031948)
41. Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy.
Hu X; Hong K; Zhao C; Zheng Y; Ma L; Ruan Y; Gao H; Greene K; Sarzotti-Kelsoe M; Montefiori DC; Shao Y
J Gen Virol; 2012 Oct; 93(Pt 10):2267-2278. PubMed ID: 22791603
[TBL] [Abstract][Full Text] [Related]
42. Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection.
Mandizvo T; Gumede N; Ndlovu B; Ndlovu S; Mann JK; Chopera DR; Singh L; Dong KL; Walker BD; Ndhlovu ZM; Lavine CL; Seaman MS; Gounder K; Ndung'u T
J Virol; 2022 Dec; 96(24):e0127022. PubMed ID: 36453881
[TBL] [Abstract][Full Text] [Related]
43. Cross-Neutralizing Antibodies in HIV-1 Individuals Infected by Subtypes B, F1, C or the B/Bbr Variant in Relation to the Genetics and Biochemical Characteristics of the env Gene.
de Almeida DV; Macieira KV; Grinsztejn BG; Veloso Dos Santos VG; Guimarães ML
PLoS One; 2016; 11(12):e0167690. PubMed ID: 27936047
[TBL] [Abstract][Full Text] [Related]
44. Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer.
Powell RLR; Totrov M; Itri V; Liu X; Fox A; Zolla-Pazner S
J Virol; 2017 Sep; 91(17):. PubMed ID: 28615206
[TBL] [Abstract][Full Text] [Related]
45. eCD4-Ig Limits HIV-1 Escape More Effectively than CD4-Ig or a Broadly Neutralizing Antibody.
Fellinger CH; Gardner MR; Weber JA; Alfant B; Zhou AS; Farzan M
J Virol; 2019 Jul; 93(14):. PubMed ID: 31068428
[TBL] [Abstract][Full Text] [Related]
46. A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.
Li L; Wang XH; Williams C; Volsky B; Steczko O; Seaman MS; Luthra K; Nyambi P; Nadas A; Giudicelli V; Lefranc MP; Zolla-Pazner S; Gorny MK
Mol Immunol; 2015 Aug; 66(2):364-74. PubMed ID: 25965315
[TBL] [Abstract][Full Text] [Related]
47. A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies.
Fetzer I; Davis-Gardner ME; Gardner MR; Alfant B; Weber JA; Prasad NR; Zhou AS; Farzan M
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541842
[TBL] [Abstract][Full Text] [Related]
48. Antigenic conservation and immunogenicity of the HIV coreceptor binding site.
Decker JM; Bibollet-Ruche F; Wei X; Wang S; Levy DN; Wang W; Delaporte E; Peeters M; Derdeyn CA; Allen S; Hunter E; Saag MS; Hoxie JA; Hahn BH; Kwong PD; Robinson JE; Shaw GM
J Exp Med; 2005 May; 201(9):1407-19. PubMed ID: 15867093
[TBL] [Abstract][Full Text] [Related]
49. Evolution of cross-neutralizing antibodies and mapping epitope specificity in plasma of chronic HIV-1-infected antiretroviral therapy-naïve children from India.
Makhdoomi MA; Khan L; Kumar S; Aggarwal H; Singh R; Lodha R; Singla M; Das BK; Kabra SK; Luthra K
J Gen Virol; 2017 Jul; 98(7):1879-1891. PubMed ID: 28696188
[TBL] [Abstract][Full Text] [Related]
50. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
51. Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope.
van Dorsten RT; Lambson BE; Wibmer CK; Weinberg MS; Moore PL; Morris L
J Virol; 2020 Jan; 94(2):. PubMed ID: 31619559
[TBL] [Abstract][Full Text] [Related]
52. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
[TBL] [Abstract][Full Text] [Related]
53. Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes.
Ringe RP; Pugach P; Cottrell CA; LaBranche CC; Seabright GE; Ketas TJ; Ozorowski G; Kumar S; Schorcht A; van Gils MJ; Crispin M; Montefiori DC; Wilson IA; Ward AB; Sanders RW; Klasse PJ; Moore JP
J Virol; 2019 Feb; 93(4):. PubMed ID: 30487280
[TBL] [Abstract][Full Text] [Related]
54. Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection.
Ndlovu B; Gounder K; Muema D; Raju N; Hermanus T; Mthethwa Q; Robertson K; Walker BD; Georgiev IS; Morris L; Moore PL; Ndung'u T
Virology; 2020 Jul; 546():1-12. PubMed ID: 32275203
[TBL] [Abstract][Full Text] [Related]
55. Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies.
Hraber P; Korber BT; Lapedes AS; Bailer RT; Seaman MS; Gao H; Greene KM; McCutchan F; Williamson C; Kim JH; Tovanabutra S; Hahn BH; Swanstrom R; Thomson MM; Gao F; Harris L; Giorgi E; Hengartner N; Bhattacharya T; Mascola JR; Montefiori DC
J Virol; 2014 Nov; 88(21):12623-43. PubMed ID: 25142591
[TBL] [Abstract][Full Text] [Related]
56. Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response.
Dubrovskaya V; Guenaga J; de Val N; Wilson R; Feng Y; Movsesyan A; Karlsson Hedestam GB; Ward AB; Wyatt RT
PLoS Pathog; 2017 Sep; 13(9):e1006614. PubMed ID: 28902916
[TBL] [Abstract][Full Text] [Related]
57. Global Increases in Human Immunodeficiency Virus Neutralization Sensitivity Due to Alterations in the Membrane-Proximal External Region of the Envelope Glycoprotein Can Be Minimized by Distant State 1-Stabilizing Changes.
Wang Q; Esnault F; Zhao M; Chiu TJ; Smith AB; Nguyen HT; Sodroski JG
J Virol; 2022 Apr; 96(7):e0187821. PubMed ID: 35289647
[TBL] [Abstract][Full Text] [Related]
58. Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.
Dieltjens T; Heyndrickx L; Willems B; Gray E; Van Nieuwenhove L; Grupping K; Vanham G; Janssens W
Retrovirology; 2009 Dec; 6():113. PubMed ID: 20003438
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of susceptibility of HIV-1 CRF01_AE variants to neutralization by a panel of broadly neutralizing antibodies.
Wang H; Yuan T; Li T; Li Y; Qian F; Zhu C; Liang S; Hoffmann D; Dittmer U; Sun B; Yang R
Arch Virol; 2018 Dec; 163(12):3303-3315. PubMed ID: 30196320
[TBL] [Abstract][Full Text] [Related]
60. Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41.
Lai RP; Yan J; Heeney J; McClure MO; Göttlinger H; Luban J; Pizzato M
PLoS Pathog; 2011 Dec; 7(12):e1002442. PubMed ID: 22194689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
